|
|
Home
: Clinical Trials, Guidelines, and Reports : Journal
Article Reprints
| |
Journal Article Reprints
These reprints are copies of journal articles about the Diabetes
Control and Complications Trial and other National Institute of
Diabetes and Digestive and Kidney Diseases research programs. Please
indicate the articles you would like to order. Single copies only
are available.
| ______ (DMR-21) |
Klaff, L. J., Tamborlane, W. V., Cleary, P. A.,
Steffes, M. W., & Becker, D. J. (1987). Effects of age, duration
and treatment of insulin-dependent diabetes mellitus on residual
ß-cell function: Observations during eligibility testing
for the Diabetes Control and Complications Trial (DCCT). Journal
of Clinical Endocrinology and Metabolism, 65 (1), 30–36. |
| ______ (DMR-22) |
Rand, L. I., Davis, M. D., Hubbard, L. D., Segal,
P., & Cleary, P. A. (1987). Color photography vs. fluorescein
angiography in the detection of diabetic retinopathy in the
Diabetes Control and Complications Trial. Archives of Ophthalmology,
105, 1344–1351. |
| ______ (DMR-23) |
The Diabetes Control and Complications Trial Research
Group. (1988). Sounding board: Are continuing studies of metabolic
control and microvascular complications in insulin-dependent
diabetes mellitus justified? The New England Journal of Medicine,
318, 246–250. |
| ______ (DMR-24) |
Greene, D., Brown, M. J., Pfeifer, M., Cleary,
P. A., & Gilbert, P. R. (1988). Factors in development of diabetic
neuropathy: Baseline analysis of neuropathy in feasibility phase
of Diabetes Control and Complications Trial (DCCT). Diabetes,
37 (4), 476–481. |
| ______ (DMR-25) |
Goldstein, D. E., Soeldner, S., Cleary, P. A.,
& Nathan, D. M. (1987). Feasibility of centralized measurements
of glycated hemoglobin in the Diabetes Control and Complications
Trial: A multicenter study. Clinical Chemistry, 33 (12),
2267–2271. |
| ______ (DMR-26) |
Wing, R. R., & Cleary, P. A. (1988). Weight gain
associated with intensive therapy in the Diabetes Control and
Complications Trial. Diabetes Care, 11 (7), 567–573. |
| ______ (DMR-28) |
Jacobson, A., Barofsky, I., Cleary, P., & Rand,
L. (1988). Reliability and validity of a diabetes quality-of-life
measure for the Diabetes Control and Complications Trial (DCCT).
Diabetes Care, 11 (9), 725–732. |
| ______ (DMR-29) |
The Diabetes Control and Complications Trial Research
Group. (1990). Diabetes Control and Complications Trial (DCCT):
Update. Diabetes Care, 13 (4), 427–433. |
| ______ (DMR-30) |
Ahern, J., Kruger, D. F., Gatcomb, P. M., Petit,
W. A., & Tamborlane, W. V. (1989). The Diabetes Control and
Complications Trial (DCCT): The trial coordinator perspective.
The Diabetes Educator, 15 (3), 236–241. |
| ______ (DMR-31) |
Lorenz, R. A., Santiago, J. V., Siebert, C., Cleary,
P. A., & Heyse, S. (1991). Epidemiology of severe hypoglycemia
in the Diabetes Control and Complications Trial. The American
Journal of Medicine, 90, 450–459. |
| ______ (DMR-32) |
The Diabetes Control and Complications Trial Research
Group. (1992). Lipid and lipoprotein levels in patients with
IDDM. Diabetes Care, 15 (7), 886–894. |
| ______ (DMR-33) |
Molitch, M. E., Steffes, M. W., Cleary, P. A.,
& Nathan, D. M. (1993). Baseline analysis of renal function
in the Diabetes Control and Complications Trial. Kidney International,
43, 668–674. |
| ______ (DMR-34) |
Siebert, C., Lipsett, L. F., Greenblatt, J., &
Silverman, R. E. (1993). Survey of physician practice behaviors
related to diabetes mellitus in the U.S. Diabetes Care, 42
(16), 759–764. |
| ______ (DMR-35) |
The Diabetes Control and Complications Trial Research
Group. (1993). The effect of intensive treatment of diabetes
on the development and progression of long-term complications
in insulin-dependent diabetes mellitus. The New England Journal
of Medicine, 329, 977–986. |
| ______ (DMR-36) |
Lan, S. P., Ryan, C. M., Adams, K. M., Grant,
I., Heaton, R. K., & Rand, L. I. (1994). A screening algorithm
to identify clinically significant changes in neuropsychological
functions in the Diabetes Control and Complications Trial. Journal
of Clinical and Experimental Neuropsychology, 16 (2), 303–316. |
| ______ (DMR-37) |
Delahanty, L., Simkins, S. W., & Camelon, K. (1993).
Expanded role of the dietitian in the Diabetes Control and Complications
Trial: Implications for clinical practice. Journal of the
American Dietetic Association, 93 (7), 758–767. |
| ______ (DMR-38) |
Anderson, E. J., Richardson, M., Castle, G., Cercone,
S., Delahanty, L., & Lyon, R. (1993). Nutrition interventions
for intensive therapy in the Diabetes Control and Complications
Trial. Journal of the American Dietetic Association, 93
(7), 768–772. |
| ______ (DMR-39) |
Diabetes Control and Complications Trial Research
Group. (1994). Effect of intensive diabetes treatment on the
development and progression of long-term complications in adolescents
with insulin-dependent diabetes mellitus: Diabetes Control and
Complications Trial. The Journal of Pediatrics, 125 (2),
177–188. |
| ______ (DMR-40) |
Diabetes Control and Complications Trial Research
Group. (1995). Implementation of treatment protocols in the
Diabetes Control and Complications Trial. Diabetes Care,
18 (3), 361–376. |
| ______ (DMR-41) |
The Diabetes Control and Complications Trial Research
Group. (1995). The effect of intensive diabetes therapy on the
development and progression of neuropathy. Annals of Internal
Medicine, 122 (8), 561–568. |
| ______ (DMR-42) |
Leiter, L. A., Lukaski, H. C., Kenny, D. J., Barnie,
A., & Camelon, K. (1994). The use of bioelectrical impedance
analysis (BIA) to estimate body composition in the Diabetes
Control and Complications Trial (DCCT). International Journal
of Obesity, 18, 829–835. |
| ______ (DMR-43) |
Diabetes Control and Complications Trial Research
Group. (1995). Progression of retinopathy with intensive versus
conventional treatment in the Diabetes Control and Complications
Trial. Ophthalmology, 102 (4), 647–661. |
| ______ (DMR-44) |
The Diabetes Control and Complications Trial Research
Group. (1995). Effect of intensive therapy on the development
and progression of diabetic nephropathy in the Diabetes Control
and Complications Trial. Kidney International, 47, 1703–1720. |
| ______ (DMR-45) |
The Diabetes Control and Complications Trial (DCCT)
Research Group. (1995). Effect of intensive diabetes management
on macrovascular events and risk factors in the Diabetes Control
and Complications Trial. The American Journal of Cardiology,
75, 894–903. |
| ______ (DMR-46) |
The Diabetes Control and Complications Trial Research
Group. (1995). The relationship of glycemic exposure (HbA1c)
to the risk of development and progression of retinopathy in
the Diabetes Control and Complications Trial. Diabetes, 44,
968–983. |
| ______ (DMR-47) |
The Diabetes Control and Complications Trial Research
Group. (1995). Adverse events and their association with treatment
regimens in the Diabetes Control and Complications Trial. Diabetes
Care, 18 (11), 1415–1427. |
| ______ (DMR-48) |
The Diabetes Control and Complications Trial Research
Group. (1995). Resource utilization and costs of care in the
Diabetes Control and Complications Trial. Diabetes Care,
18 (11), 1468–1478. |
| ______ (DMR-49) |
The Diabetes Control and Complications Trial Research
Group. (1995). A comparison of the study populations in the
Diabetes Control and Complications Trial and the Wisconsin Epidemiologic
Study of Diabetic Retinopathy. Archives of Internal Medicine,
155, 745–754. |
| ______ (DMR-50) |
The Diabetes Control and Complications Trial Research
Group. (1995). Effect of intensive diabetes treatment on nerve
conduction in the Diabetes Control and Complications Trial.
Annals of Neurology, 38 (6), 869–880. |
| ______ (DMR-51) |
The Diabetes Control and Complications Trial Research
Group. (1996). Effects of intensive diabetes therapy on neuropsychological
function in adults in the Diabetes Control and Complications
Trial. Annals of Internal Medicine, 124 (4), 379–388. |
| ______ (DMR-52) |
The Diabetes Control and Complications Trial Research
Group. (1996). Influence of intensive diabetes treatment on
quality-of-life outcomes in the Diabetes Control and Complications
Trial. Diabetes Care, 19 (3), 195–203. |
| ______ (DMR-53) |
The Diabetes Control and Complications Trial Research
Group. (1995). The effect of intensive diabetes treatment on
the progression of diabetic retinopathy in insulin-dependent
diabetes mellitus. Archives of Ophthalmology, 113, 36–51. |
| ______ (DMR-54) |
The Diabetes Control and Complications Trial Research
Group. (1996). Pregnancy outcomes in the Diabetes Control and
Complications Trial. American Journal of Obstetrics and Gynecology,
174, 1343–1353. |
| ______ (DMR-55) |
The Diabetes Control and Complications Trial Research
Group. (1996). The absence of a glycemic threshold for the development
of long-term complications: The perspective of the Diabetes
Control and Complications Trial. Diabetes, 45, 1289–1298. |
| ______ (DMR-56) |
The Diabetes Control and Complications Trial Research
Group. (1997). Hypoglycemia in the Diabetes Control and Complications
Trial. Diabetes, 46, 271–286. |
| ______ (DMR-57) |
The Diabetes Control and Complications Trial Research
Group. (1996). Lifetime benefits and costs of intensive therapy
as practiced in the Diabetes Control and Complications Trial.
Journal of the American Medical Association, 276 (17),
1409–1415. |
| ______ (DMR-58) |
The Diabetes Control and Complications Trial Research
Group. (1998). Effect of intensive therapy on residual ß-cell
function in patients with type 1 diabetes in the Diabetes Control
and Complications Trial: A randomized, controlled trial. Annals
of Internal Medicine, 128 (7), 517–523. |
| ______ (DMR-59) |
The Diabetes Control and Complications Trial Research
Group. (1997). Clustering of long-term complications in families
with diabetes in the Diabetes Control and Complications Trial.
Diabetes, 46, 1829–1839. |
| ______ (DMR-60) |
The Diabetes Control and Complications Trial Research
Group. (1998). The effect of intensive diabetes therapy on measures
of autonomic nervous system function in the Diabetes Control
and Complications Trial. Diabetologia, 41, 416–423. |
| ______ (DMR-61) |
The Diabetes Control and Complications Trial Research
Group. (1998). Early worsening of diabetic retinopathy in the
Diabetes Control and Complications Trial. Archives of Ophthalmology,
116, 874–886. |
| ______ (DMR-62) |
Epidemiology of Diabetes Interventions and Complications
(EDIC) Research Group. (1999). Epidemiology of Diabetes Interventions
and Complications (EDIC). Diabetes Care, 22 (1), 99–111.
|
| ______ (DMR-65) |
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. The New England Journal of Medicine. 2005;353(25): 2643–2653
|
|
Name______________________________________________________________
Customer ID #*______________________________________________________
Title/Organization_____________________________________________________
Address____________________________________________________________
City________________________ State______________ ZIP_________________
Telephone___________________________________________________________
*Please see the packing slip from your most recent order.
Please return this order form to
National Diabetes Information Clearinghouse
1 Information Way
Bethesda, MD 20892–3560 (Please use complete 9-digit ZIP code)
Tel: 1–800–860–8747
Fax: 703–738–4929
E-mail: ndic@info.niddk.nih.gov
|
|
|
